Clinical trials, consensus conferences, and clinical practice

Lancet

Volumn 354, Issue 9175, 1999, Pages 327-330

  Sniderman, Allan D ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DATA ANALYSIS; HUMAN; MEDICAL DECISION MAKING; METHODOLOGY; PRIORITY JOURNAL; RANDOMIZATION; SHORT SURVEY;

EID: 0033600435     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)11185-6     Document Type: Note

References (18)

1. Feinstein A.R., Horwitz R. Problems in the "evidence" of "evidence-based medicne" Am J Med. 103:1997;529-535.
2. Tonelli M.R. The philosophical limits of evidence-based medicine. Acad Med. 73:1998;1234-1240.
3. Davidson R.A. Source of funding and outcome of clinical trials. J Gen Intern Med. 1:1986;155-158.
4. Stelfox H.T., Chua G., O'Rourke K., Destsky D.A. Conflicts of interest in the debate over calcium channel antagonists. N Engl J Med. 338:1998;101-106.
5. McIntyre K.M. Medicolegal implications of the consensus conference, with special attention to the Fifth Antithrombotic Therapy Consensus. Chest. 114( suppl 5):1998;742-747.
6. Hulley S., Grady D., Bush T.et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
7. Shepherd J., Cobbe S.M., Ford I.et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
9. Sacks F.M., Pfeffer M.A., Moye L.A.et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
11. Influence of pravastatin and plasma lipids on clinical events in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 97:1998;1440-1445.
12. Downs J.R., Clearfield M., Weis S.et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279:1998;1615-1622.
13. Summary of the second report of the National Cholesterol Education Programme (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
14. Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Arteriosclerosis. 13:1993;291-298.
15. Little W.C., Constantinescu M., Applegate R.J.et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 18:1988;1157-1166.
16. Zhao X.Q., Brown B.G., Hillger L.et al. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Circulation. 88:1993;2744-2753.
17. Lamarche B., Moorjani S., Lupien P.J.et al. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation. 94:1996;273-278.
18. Lamarche B., Tchernof A., Mauriege P.et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 279:1998;1955-1961.